European equities sold off sharply in response to President Trump’s threatened tariffs on eight European countries, with major exporters under pressure. Novo Nordisk shares declined 2.96% on the day the EURO STOXX 50 fell 1.4%. Analysts at Goldman Sachs estimate a 10% U.S. tariff could shave 0.1%–0.2% off GDP in affected nations, potentially reducing Danish drug exports by up to DKK 5 billion in 2026. Investors are monitoring whether trade tensions will prompt pricing adjustments or supply diversions to non‐U.S. markets.

Novo Nordisk and Canada‐based Aspect Biosystems announced an extension of their 2023 collaboration to develop 3D bioprinted pancreatic islet tissue for diabetes treatment. Under the revised agreement, Novo Nordisk will provide up to DKK 1.2 billion in research funding over five years, with potential milestone payments of DKK 800 million tied to preclinical and Phase I achievements. The companies aim to initiate IND‐enabling studies by late 2026, targeting a first‐in‐human trial in 2028.

In its first week following the early January launch of oral Wegovy, Novo Nordisk recorded more than 12,500 U.S. prescriptions across 550 medical practices, exceeding internal projections by 35%. The product received initial coverage from 85% of commercial payers, and patient adherence rates in week one averaged 92%. Novo Nordisk’s U.S. sales force has been scaled to 400 specialized obesity managers to support expected quarterly prescriptions of 50,000 by mid-2026.

Novo Nordisk is preparing for 2026 patent expirations of semaglutide in Canada and China, which together accounted for DKK 3.5 billion in 2024 sales. CEO Mike Doustdar projects price pressure of up to 15% in those markets but aims to offset cuts with 20% volume growth driven by expanded patient access programs. The company plans targeted business development partnerships to bolster its late-stage pipeline, with a goal of announcing at least two licensing deals by the fourth quarter of 2026.